A randomized double-blind phase Ib clinical trial of SY-009 in patients with type 2 diabetes mellitus

SY-009 produces a hypoglycemic effect via inhibiting sodium/glucose cotransporter 1 (SGLT1) in type 2 diabetes mellitus (T2DM) patients. This randomized, double-blind, placebo-controlled, and multiple-dose escalation clinical trial aimed to evaluate the pharmacokinetic and pharmacodynamical characte...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of pharmaceutical sciences 2024-01, Vol.192, p.106644-106644, Article 106644
Hauptverfasser:	Huang, Lei, Cao, Bei, Geng, Yan, Zhou, Xiaoli, Yang, Yuanxun, Ma, Tingting, Lin, Hui, Huang, Zhijiang, Zhuo, Lang, Li, Juan
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood Glucose C-Peptide - therapeutic use Clinical trial Diabetes Mellitus, Type 2 - metabolism Double-Blind Method Gastric Inhibitory Polypeptide - adverse effects Gastric Inhibitory Polypeptide - metabolism Glucagon-Like Peptide 1 Glucose Humans Hypoglycemic Agents Insulin - therapeutic use SGLT1 inhibitor Type 2 diabetes mellitus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!